PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
18480028-5	2008	In ACAT2, H438 was required for enzymatic activity.	1-(2-hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo(d)thiazol-2-yl)urea	10-14	acetyl-CoA acetyltransferase 2	Homo sapiens	3-8
24657654-0	2014	HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.	1-(2-hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo(d)thiazol-2-yl)urea	0-6	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	46-53
24657654-3	2014	In the present study, we synthesized a novel BCR-ABL inhibitor, HS-438, and identified its anti-leukemic effects in vitro and in vivo.	1-(2-hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo(d)thiazol-2-yl)urea	64-70	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	45-52
24657654-4	2014	We found that HS-438 strongly inhibited the expression of BCR-ABL signaling pathways in wild-type BCR-ABL (BaF3/WT) cells as well as T315I-mutated BCR-ABL (BaF3/T315I) cells with resistance to imatinib.	1-(2-hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo(d)thiazol-2-yl)urea	14-20	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	58-65
24657654-4	2014	We found that HS-438 strongly inhibited the expression of BCR-ABL signaling pathways in wild-type BCR-ABL (BaF3/WT) cells as well as T315I-mutated BCR-ABL (BaF3/T315I) cells with resistance to imatinib.	1-(2-hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo(d)thiazol-2-yl)urea	14-20	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	98-105
24657654-4	2014	We found that HS-438 strongly inhibited the expression of BCR-ABL signaling pathways in wild-type BCR-ABL (BaF3/WT) cells as well as T315I-mutated BCR-ABL (BaF3/T315I) cells with resistance to imatinib.	1-(2-hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo(d)thiazol-2-yl)urea	14-20	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	98-105
24657654-7	2014	In summary, we suggest that HS-438 may be a novel drug candidate with the therapeutic potential to target BCR-ABL and overcome imatinib resistance in patients with CML.	1-(2-hydroxyethyl)-3-(6-(2-methoxyphenyl)benzo(d)thiazol-2-yl)urea	28-34	ABL proto-oncogene 1, non-receptor tyrosine kinase	Homo sapiens	106-113